GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpha Teknova Inc (NAS:TKNO) » Definitions » Sloan Ratio %

Alpha Teknova (Alpha Teknova) Sloan Ratio % : -12.38% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Teknova Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Alpha Teknova's Sloan Ratio for the quarter that ended in Mar. 2024 was -12.38%.

As of Mar. 2024, Alpha Teknova has a Sloan Ratio of -12.38%, indicating there is a warning stage of accrual build up.


Alpha Teknova Sloan Ratio % Historical Data

The historical data trend for Alpha Teknova's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Teknova Sloan Ratio % Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
8.00 4.45 10.08 5.31 -7.95

Alpha Teknova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 -4.43 -2.25 -7.95 -12.38

Competitive Comparison of Alpha Teknova's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Teknova's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Alpha Teknova's Sloan Ratio % falls into.



Alpha Teknova Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Alpha Teknova's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-36.78--18.814
--7.737)/128.587
=-7.95%

Alpha Teknova's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-36.06--17.688
--3.412)/120.817
=-12.38%

Alpha Teknova's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -7.154 (Jun. 2023 ) + -10.153 (Sep. 2023 ) + -10.656 (Dec. 2023 ) + -8.097 (Mar. 2024 ) = $-36.06 Mil.
Alpha Teknova's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -3.856 (Jun. 2023 ) + -4.382 (Sep. 2023 ) + -2.892 (Dec. 2023 ) + -6.558 (Mar. 2024 ) = $-17.69 Mil.
Alpha Teknova's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -2.338 (Jun. 2023 ) + -0.972 (Sep. 2023 ) + -0.115 (Dec. 2023 ) + 0.013 (Mar. 2024 ) = $-3.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Teknova  (NAS:TKNO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Alpha Teknova has a Sloan Ratio of -12.38%, indicating there is a warning stage of accrual build up.


Alpha Teknova Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Alpha Teknova's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Teknova (Alpha Teknova) Business Description

Traded in Other Exchanges
N/A
Address
2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Executives
Ken Gelhaus officer: Chief Commercial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Stephen Gunstream director, officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
J Matthew Mackowski director 343 SANSOME ST, SUITE 1215, SANSASAN FRANCISCO CA 94104
Matthew Lowell officer: Chief Financial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Damon Terrill officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
Thp Iv Affiliates Fund, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Lisa Hood officer: Chief People Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Irene Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Ted Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Iv, L.p. 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO MA 94108
Paul David Grossman director 1600 FARADAY AVENUE, CARLSBAD CA 92008
Brett Robertson director C/O INVUITY, INC., 444 DE HARO STREET, SAN FRANCOSCO CA 94107
Alexander C. Herzick director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Management Company, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108

Alpha Teknova (Alpha Teknova) Headlines